Remicade Biosimilar Industry Research Report 2025
Description
Summary
According to APO Research, the global Remicade Biosimilar market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Remicade Biosimilar is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Remicade Biosimilar is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Remicade Biosimilar is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Remicade Biosimilar include Walvax Biotechnology, Livzon Pharmaceutical, Hualan Biological Engineering, Hisun Pharmaceutical, Fosun Pharmaceutical, Anke Biotechnology, Synthon Pharmaceuticals, Novartis (Sandoz) and Merck Serono (Merck Group), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Remicade Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Remicade Biosimilar.
The report will help the Remicade Biosimilar manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Remicade Biosimilar market size, estimations, and forecasts are provided in terms of sales volume (L) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Remicade Biosimilar market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Remicade Biosimilar Segment by Company
Walvax Biotechnology
Livzon Pharmaceutical
Hualan Biological Engineering
Hisun Pharmaceutical
Fosun Pharmaceutical
Anke Biotechnology
Synthon Pharmaceuticals
Novartis (Sandoz)
Merck Serono (Merck Group)
LG Life Sciences
Hospira
Genentech (Roche Group)
Celltrion
Biogen idec Inc.
Biocon
Remicade Biosimilar Segment by Type
100mg/10ml
500mg/50ml
Remicade Biosimilar Segment by Application
Blood Disorders
Oncology Diseases
Remicade Biosimilar Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Remicade Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Remicade Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Remicade Biosimilar.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Remicade Biosimilar manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Remicade Biosimilar by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Remicade Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
According to APO Research, the global Remicade Biosimilar market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Remicade Biosimilar is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Remicade Biosimilar is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Remicade Biosimilar is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Remicade Biosimilar include Walvax Biotechnology, Livzon Pharmaceutical, Hualan Biological Engineering, Hisun Pharmaceutical, Fosun Pharmaceutical, Anke Biotechnology, Synthon Pharmaceuticals, Novartis (Sandoz) and Merck Serono (Merck Group), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Remicade Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Remicade Biosimilar.
The report will help the Remicade Biosimilar manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Remicade Biosimilar market size, estimations, and forecasts are provided in terms of sales volume (L) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Remicade Biosimilar market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Remicade Biosimilar Segment by Company
Walvax Biotechnology
Livzon Pharmaceutical
Hualan Biological Engineering
Hisun Pharmaceutical
Fosun Pharmaceutical
Anke Biotechnology
Synthon Pharmaceuticals
Novartis (Sandoz)
Merck Serono (Merck Group)
LG Life Sciences
Hospira
Genentech (Roche Group)
Celltrion
Biogen idec Inc.
Biocon
Remicade Biosimilar Segment by Type
100mg/10ml
500mg/50ml
Remicade Biosimilar Segment by Application
Blood Disorders
Oncology Diseases
Remicade Biosimilar Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Remicade Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Remicade Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Remicade Biosimilar.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Remicade Biosimilar manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Remicade Biosimilar by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Remicade Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Table of Contents
131 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Remicade Biosimilar Market Size (2020-2031)
- 2.2.2 Global Remicade Biosimilar Sales (2020-2031)
- 2.2.3 Global Remicade Biosimilar Market Average Price (2020-2031)
- 2.3 Remicade Biosimilar by Type
- 2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- 2.3.2 100mg/10ml
- 2.3.3 500mg/50ml
- 2.4 Remicade Biosimilar by Application
- 2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.4.2 Blood Disorders
- 2.4.3 Oncology Diseases
- 3 Market Competitive Landscape by Manufacturers
- 3.1 Global Remicade Biosimilar Market Competitive Situation by Manufacturers (2020 Versus 2024)
- 3.2 Global Remicade Biosimilar Sales (L) of Manufacturers (2020-2025)
- 3.3 Global Remicade Biosimilar Revenue of Manufacturers (2020-2025)
- 3.4 Global Remicade Biosimilar Average Price by Manufacturers (2020-2025)
- 3.5 Global Remicade Biosimilar Industry Ranking, 2023 VS 2024 VS 2025
- 3.6 Global Manufacturers of Remicade Biosimilar, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Remicade Biosimilar, Product Type & Application
- 3.8 Global Manufacturers of Remicade Biosimilar, Established Date
- 3.9 Global Remicade Biosimilar Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
- 4 Manufacturers Profiled
- 4.1 Walvax Biotechnology
- 4.1.1 Walvax Biotechnology Company Information
- 4.1.2 Walvax Biotechnology Business Overview
- 4.1.3 Walvax Biotechnology Remicade Biosimilar Sales, Revenue and Gross Margin (2020-2025)
- 4.1.4 Walvax Biotechnology Remicade Biosimilar Product Portfolio
- 4.1.5 Walvax Biotechnology Recent Developments
- 4.2 Livzon Pharmaceutical
- 4.2.1 Livzon Pharmaceutical Company Information
- 4.2.2 Livzon Pharmaceutical Business Overview
- 4.2.3 Livzon Pharmaceutical Remicade Biosimilar Sales, Revenue and Gross Margin (2020-2025)
- 4.2.4 Livzon Pharmaceutical Remicade Biosimilar Product Portfolio
- 4.2.5 Livzon Pharmaceutical Recent Developments
- 4.3 Hualan Biological Engineering
- 4.3.1 Hualan Biological Engineering Company Information
- 4.3.2 Hualan Biological Engineering Business Overview
- 4.3.3 Hualan Biological Engineering Remicade Biosimilar Sales, Revenue and Gross Margin (2020-2025)
- 4.3.4 Hualan Biological Engineering Remicade Biosimilar Product Portfolio
- 4.3.5 Hualan Biological Engineering Recent Developments
- 4.4 Hisun Pharmaceutical
- 4.4.1 Hisun Pharmaceutical Company Information
- 4.4.2 Hisun Pharmaceutical Business Overview
- 4.4.3 Hisun Pharmaceutical Remicade Biosimilar Sales, Revenue and Gross Margin (2020-2025)
- 4.4.4 Hisun Pharmaceutical Remicade Biosimilar Product Portfolio
- 4.4.5 Hisun Pharmaceutical Recent Developments
- 4.5 Fosun Pharmaceutical
- 4.5.1 Fosun Pharmaceutical Company Information
- 4.5.2 Fosun Pharmaceutical Business Overview
- 4.5.3 Fosun Pharmaceutical Remicade Biosimilar Sales, Revenue and Gross Margin (2020-2025)
- 4.5.4 Fosun Pharmaceutical Remicade Biosimilar Product Portfolio
- 4.5.5 Fosun Pharmaceutical Recent Developments
- 4.6 Anke Biotechnology
- 4.6.1 Anke Biotechnology Company Information
- 4.6.2 Anke Biotechnology Business Overview
- 4.6.3 Anke Biotechnology Remicade Biosimilar Sales, Revenue and Gross Margin (2020-2025)
- 4.6.4 Anke Biotechnology Remicade Biosimilar Product Portfolio
- 4.6.5 Anke Biotechnology Recent Developments
- 4.7 Synthon Pharmaceuticals
- 4.7.1 Synthon Pharmaceuticals Company Information
- 4.7.2 Synthon Pharmaceuticals Business Overview
- 4.7.3 Synthon Pharmaceuticals Remicade Biosimilar Sales, Revenue and Gross Margin (2020-2025)
- 4.7.4 Synthon Pharmaceuticals Remicade Biosimilar Product Portfolio
- 4.7.5 Synthon Pharmaceuticals Recent Developments
- 4.8 Novartis (Sandoz)
- 4.8.1 Novartis (Sandoz) Company Information
- 4.8.2 Novartis (Sandoz) Business Overview
- 4.8.3 Novartis (Sandoz) Remicade Biosimilar Sales, Revenue and Gross Margin (2020-2025)
- 4.8.4 Novartis (Sandoz) Remicade Biosimilar Product Portfolio
- 4.8.5 Novartis (Sandoz) Recent Developments
- 4.9 Merck Serono (Merck Group)
- 4.9.1 Merck Serono (Merck Group) Company Information
- 4.9.2 Merck Serono (Merck Group) Business Overview
- 4.9.3 Merck Serono (Merck Group) Remicade Biosimilar Sales, Revenue and Gross Margin (2020-2025)
- 4.9.4 Merck Serono (Merck Group) Remicade Biosimilar Product Portfolio
- 4.9.5 Merck Serono (Merck Group) Recent Developments
- 4.10 LG Life Sciences
- 4.10.1 LG Life Sciences Company Information
- 4.10.2 LG Life Sciences Business Overview
- 4.10.3 LG Life Sciences Remicade Biosimilar Sales, Revenue and Gross Margin (2020-2025)
- 4.10.4 LG Life Sciences Remicade Biosimilar Product Portfolio
- 4.10.5 LG Life Sciences Recent Developments
- 4.11 Hospira
- 4.11.1 Hospira Company Information
- 4.11.2 Hospira Business Overview
- 4.11.3 Hospira Remicade Biosimilar Sales, Revenue and Gross Margin (2020-2025)
- 4.11.4 Hospira Remicade Biosimilar Product Portfolio
- 4.11.5 Hospira Recent Developments
- 4.12 Genentech (Roche Group)
- 4.12.1 Genentech (Roche Group) Company Information
- 4.12.2 Genentech (Roche Group) Business Overview
- 4.12.3 Genentech (Roche Group) Remicade Biosimilar Sales, Revenue and Gross Margin (2020-2025)
- 4.12.4 Genentech (Roche Group) Remicade Biosimilar Product Portfolio
- 4.12.5 Genentech (Roche Group) Recent Developments
- 4.13 Celltrion
- 4.13.1 Celltrion Company Information
- 4.13.2 Celltrion Business Overview
- 4.13.3 Celltrion Remicade Biosimilar Sales, Revenue and Gross Margin (2020-2025)
- 4.13.4 Celltrion Remicade Biosimilar Product Portfolio
- 4.13.5 Celltrion Recent Developments
- 4.14 Biogen idec Inc.
- 4.14.1 Biogen idec Inc. Company Information
- 4.14.2 Biogen idec Inc. Business Overview
- 4.14.3 Biogen idec Inc. Remicade Biosimilar Sales, Revenue and Gross Margin (2020-2025)
- 4.14.4 Biogen idec Inc. Remicade Biosimilar Product Portfolio
- 4.14.5 Biogen idec Inc. Recent Developments
- 4.15 Biocon
- 4.15.1 Biocon Company Information
- 4.15.2 Biocon Business Overview
- 4.15.3 Biocon Remicade Biosimilar Sales, Revenue and Gross Margin (2020-2025)
- 4.15.4 Biocon Remicade Biosimilar Product Portfolio
- 4.15.5 Biocon Recent Developments
- 5 Global Remicade Biosimilar Market Scenario by Region
- 5.1 Global Remicade Biosimilar Market Size by Region: 2020 VS 2024 VS 2031
- 5.2 Global Remicade Biosimilar Sales by Region: 2020-2031
- 5.2.1 Global Remicade Biosimilar Sales by Region: 2020-2025
- 5.2.2 Global Remicade Biosimilar Sales by Region: 2026-2031
- 5.3 Global Remicade Biosimilar Revenue by Region: 2020-2031
- 5.3.1 Global Remicade Biosimilar Revenue by Region: 2020-2025
- 5.3.2 Global Remicade Biosimilar Revenue by Region: 2026-2031
- 5.4 North America Remicade Biosimilar Market Facts & Figures by Country
- 5.4.1 North America Remicade Biosimilar Market Size by Country: 2020 VS 2024 VS 2031
- 5.4.2 North America Remicade Biosimilar Sales by Country (2020-2031)
- 5.4.3 North America Remicade Biosimilar Revenue by Country (2020-2031)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Remicade Biosimilar Market Facts & Figures by Country
- 5.5.1 Europe Remicade Biosimilar Market Size by Country: 2020 VS 2024 VS 2031
- 5.5.2 Europe Remicade Biosimilar Sales by Country (2020-2031)
- 5.5.3 Europe Remicade Biosimilar Revenue by Country (2020-2031)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Remicade Biosimilar Market Facts & Figures by Country
- 5.6.1 Asia Pacific Remicade Biosimilar Market Size by Country: 2020 VS 2024 VS 2031
- 5.6.2 Asia Pacific Remicade Biosimilar Sales by Country (2020-2031)
- 5.6.3 Asia Pacific Remicade Biosimilar Revenue by Country (2020-2031)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Remicade Biosimilar Market Facts & Figures by Country
- 5.7.1 South America Remicade Biosimilar Market Size by Country: 2020 VS 2024 VS 2031
- 5.7.2 South America Remicade Biosimilar Sales by Country (2020-2031)
- 5.7.3 South America Remicade Biosimilar Revenue by Country (2020-2031)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Remicade Biosimilar Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Remicade Biosimilar Market Size by Country: 2020 VS 2024 VS 2031
- 5.8.2 Middle East and Africa Remicade Biosimilar Sales by Country (2020-2031)
- 5.8.3 Middle East and Africa Remicade Biosimilar Revenue by Country (2020-2031)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
- 6 Segment by Type
- 6.1 Global Remicade Biosimilar Sales by Type (2020-2031)
- 6.1.1 Global Remicade Biosimilar Sales by Type (2020-2031) & (L)
- 6.1.2 Global Remicade Biosimilar Sales Market Share by Type (2020-2031)
- 6.2 Global Remicade Biosimilar Revenue by Type (2020-2031)
- 6.2.1 Global Remicade Biosimilar Sales by Type (2020-2031) & (US$ Million)
- 6.2.2 Global Remicade Biosimilar Revenue Market Share by Type (2020-2031)
- 6.3 Global Remicade Biosimilar Price by Type (2020-2031)
- 7 Segment by Application
- 7.1 Global Remicade Biosimilar Sales by Application (2020-2031)
- 7.1.1 Global Remicade Biosimilar Sales by Application (2020-2031) & (L)
- 7.1.2 Global Remicade Biosimilar Sales Market Share by Application (2020-2031)
- 7.2 Global Remicade Biosimilar Revenue by Application (2020-2031)
- 7.2.1 Global Remicade Biosimilar Sales by Application (2020-2031) & (US$ Million)
- 7.2.2 Global Remicade Biosimilar Revenue Market Share by Application (2020-2031)
- 7.3 Global Remicade Biosimilar Price by Application (2020-2031)
- 8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Remicade Biosimilar Value Chain Analysis
- 8.1.1 Remicade Biosimilar Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Remicade Biosimilar Production Mode & Process
- 8.2 Remicade Biosimilar Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Remicade Biosimilar Distributors
- 8.2.3 Remicade Biosimilar Customers
- 9 Global Remicade Biosimilar Analyzing Market Dynamics
- 9.1 Remicade Biosimilar Industry Trends
- 9.2 Remicade Biosimilar Industry Drivers
- 9.3 Remicade Biosimilar Industry Opportunities and Challenges
- 9.4 Remicade Biosimilar Industry Restraints
- 10 Report Conclusion
- 11 Disclaimer
- List of Tables
- Table 1. Secondary Sources
- Table 2. Primary Sources
- Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Table 5. Global Remicade Biosimilar Volume and Revenue Market Size and CAGR of Manufacturers (2020 Versus 2024)
- Table 6. Global Remicade Biosimilar Sales (L) of Manufacturers (2020-2025)
- Table 7. Global Remicade Biosimilar Sales Market Share by Manufacturers (2020-2025)
- Table 8. Global Remicade Biosimilar Revenue of Manufacturers (2020-2025)
- Table 9. Global Remicade Biosimilar Revenue Share by Manufacturers (2020-2025)
- Table 10. Global Market Remicade Biosimilar Average Price (US$/L) of Manufacturers (2020-2025)
- Table 11. Global Remicade Biosimilar Industry Ranking, 2023 VS 2024 VS 2025
- Table 12. Global Manufacturers of Remicade Biosimilar, Manufacturing Sites & Headquarters
- Table 13. Global Manufacturers of Remicade Biosimilar, Product Type & Application
- Table 14. Global Remicade Biosimilar Manufacturers Established Date
- Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16. Global Remicade Biosimilar by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
- Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18. Walvax Biotechnology Company Information
- Table 19. Walvax Biotechnology Business Overview
- Table 20. Walvax Biotechnology Remicade Biosimilar Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2020-2025)
- Table 21. Walvax Biotechnology Remicade Biosimilar Product Portfolio
- Table 22. Walvax Biotechnology Recent Developments
- Table 23. Livzon Pharmaceutical Company Information
- Table 24. Livzon Pharmaceutical Business Overview
- Table 25. Livzon Pharmaceutical Remicade Biosimilar Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2020-2025)
- Table 26. Livzon Pharmaceutical Remicade Biosimilar Product Portfolio
- Table 27. Livzon Pharmaceutical Recent Developments
- Table 28. Hualan Biological Engineering Company Information
- Table 29. Hualan Biological Engineering Business Overview
- Table 30. Hualan Biological Engineering Remicade Biosimilar Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2020-2025)
- Table 31. Hualan Biological Engineering Remicade Biosimilar Product Portfolio
- Table 32. Hualan Biological Engineering Recent Developments
- Table 33. Hisun Pharmaceutical Company Information
- Table 34. Hisun Pharmaceutical Business Overview
- Table 35. Hisun Pharmaceutical Remicade Biosimilar Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2020-2025)
- Table 36. Hisun Pharmaceutical Remicade Biosimilar Product Portfolio
- Table 37. Hisun Pharmaceutical Recent Developments
- Table 38. Fosun Pharmaceutical Company Information
- Table 39. Fosun Pharmaceutical Business Overview
- Table 40. Fosun Pharmaceutical Remicade Biosimilar Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2020-2025)
- Table 41. Fosun Pharmaceutical Remicade Biosimilar Product Portfolio
- Table 42. Fosun Pharmaceutical Recent Developments
- Table 43. Anke Biotechnology Company Information
- Table 44. Anke Biotechnology Business Overview
- Table 45. Anke Biotechnology Remicade Biosimilar Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2020-2025)
- Table 46. Anke Biotechnology Remicade Biosimilar Product Portfolio
- Table 47. Anke Biotechnology Recent Developments
- Table 48. Synthon Pharmaceuticals Company Information
- Table 49. Synthon Pharmaceuticals Business Overview
- Table 50. Synthon Pharmaceuticals Remicade Biosimilar Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2020-2025)
- Table 51. Synthon Pharmaceuticals Remicade Biosimilar Product Portfolio
- Table 52. Synthon Pharmaceuticals Recent Developments
- Table 53. Novartis (Sandoz) Company Information
- Table 54. Novartis (Sandoz) Business Overview
- Table 55. Novartis (Sandoz) Remicade Biosimilar Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2020-2025)
- Table 56. Novartis (Sandoz) Remicade Biosimilar Product Portfolio
- Table 57. Novartis (Sandoz) Recent Developments
- Table 58. Merck Serono (Merck Group) Company Information
- Table 59. Merck Serono (Merck Group) Business Overview
- Table 60. Merck Serono (Merck Group) Remicade Biosimilar Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2020-2025)
- Table 61. Merck Serono (Merck Group) Remicade Biosimilar Product Portfolio
- Table 62. Merck Serono (Merck Group) Recent Developments
- Table 63. LG Life Sciences Company Information
- Table 64. LG Life Sciences Business Overview
- Table 65. LG Life Sciences Remicade Biosimilar Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2020-2025)
- Table 66. LG Life Sciences Remicade Biosimilar Product Portfolio
- Table 67. LG Life Sciences Recent Developments
- Table 68. Hospira Company Information
- Table 69. Hospira Business Overview
- Table 70. Hospira Remicade Biosimilar Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2020-2025)
- Table 71. Hospira Remicade Biosimilar Product Portfolio
- Table 72. Hospira Recent Developments
- Table 73. Genentech (Roche Group) Company Information
- Table 74. Genentech (Roche Group) Business Overview
- Table 75. Genentech (Roche Group) Remicade Biosimilar Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2020-2025)
- Table 76. Genentech (Roche Group) Remicade Biosimilar Product Portfolio
- Table 77. Genentech (Roche Group) Recent Developments
- Table 78. Celltrion Company Information
- Table 79. Celltrion Business Overview
- Table 80. Celltrion Remicade Biosimilar Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2020-2025)
- Table 81. Celltrion Remicade Biosimilar Product Portfolio
- Table 82. Celltrion Recent Developments
- Table 83. Biogen idec Inc. Company Information
- Table 84. Biogen idec Inc. Business Overview
- Table 85. Biogen idec Inc. Remicade Biosimilar Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2020-2025)
- Table 86. Biogen idec Inc. Remicade Biosimilar Product Portfolio
- Table 87. Biogen idec Inc. Recent Developments
- Table 88. Biocon Company Information
- Table 89. Biocon Business Overview
- Table 90. Biocon Remicade Biosimilar Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2020-2025)
- Table 91. Biocon Remicade Biosimilar Product Portfolio
- Table 92. Biocon Recent Developments
- Table 93. Global Remicade Biosimilar Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Table 94. Global Remicade Biosimilar Sales by Region (2020-2025) & (L)
- Table 95. Global Remicade Biosimilar Sales Market Share by Region (2020-2025)
- Table 96. Global Remicade Biosimilar Sales by Region (2026-2031) & (L)
- Table 97. Global Remicade Biosimilar Sales Market Share by Region (2026-2031)
- Table 98. Global Remicade Biosimilar Revenue by Region (2020-2025) & (US$ Million)
- Table 99. Global Remicade Biosimilar Revenue Market Share by Region (2020-2025)
- Table 100. Global Remicade Biosimilar Revenue by Region (2026-2031) & (US$ Million)
- Table 101. Global Remicade Biosimilar Revenue Market Share by Region (2026-2031)
- Table 102. North America Remicade Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 103. North America Remicade Biosimilar Sales by Country (2020-2025) & (L)
- Table 104. North America Remicade Biosimilar Sales by Country (2026-2031) & (L)
- Table 105. North America Remicade Biosimilar Revenue by Country (2020-2025) & (US$ Million)
- Table 106. North America Remicade Biosimilar Revenue by Country (2026-2031) & (US$ Million)
- Table 107. Europe Remicade Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 108. Europe Remicade Biosimilar Sales by Country (2020-2025) & (L)
- Table 109. Europe Remicade Biosimilar Sales by Country (2026-2031) & (L)
- Table 110. Europe Remicade Biosimilar Revenue by Country (2020-2025) & (US$ Million)
- Table 111. Europe Remicade Biosimilar Revenue by Country (2026-2031) & (US$ Million)
- Table 112. Asia Pacific Remicade Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 113. Asia Pacific Remicade Biosimilar Sales by Country (2020-2025) & (L)
- Table 114. Asia Pacific Remicade Biosimilar Sales by Country (2026-2031) & (L)
- Table 115. Asia Pacific Remicade Biosimilar Revenue by Country (2020-2025) & (US$ Million)
- Table 116. Asia Pacific Remicade Biosimilar Revenue by Country (2026-2031) & (US$ Million)
- Table 117. South America Remicade Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 118. South America Remicade Biosimilar Sales by Country (2020-2025) & (L)
- Table 119. South America Remicade Biosimilar Sales by Country (2026-2031) & (L)
- Table 120. South America Remicade Biosimilar Revenue by Country (2020-2025) & (US$ Million)
- Table 121. South America Remicade Biosimilar Revenue by Country (2026-2031) & (US$ Million)
- Table 122. Middle East and Africa Remicade Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 123. Middle East and Africa Remicade Biosimilar Sales by Country (2020-2025) & (L)
- Table 124. Middle East and Africa Remicade Biosimilar Sales by Country (2026-2031) & (L)
- Table 125. Middle East and Africa Remicade Biosimilar Revenue by Country (2020-2025) & (US$ Million)
- Table 126. Middle East and Africa Remicade Biosimilar Revenue by Country (2026-2031) & (US$ Million)
- Table 127. Global Remicade Biosimilar Sales by Type (2020-2025) & (L)
- Table 128. Global Remicade Biosimilar Sales by Type (2026-2031) & (L)
- Table 129. Global Remicade Biosimilar Sales Market Share by Type (2020-2025)
- Table 130. Global Remicade Biosimilar Sales Market Share by Type (2026-2031)
- Table 131. Global Remicade Biosimilar Revenue by Type (2020-2025) & (US$ Million)
- Table 132. Global Remicade Biosimilar Revenue by Type (2026-2031) & (US$ Million)
- Table 133. Global Remicade Biosimilar Revenue Market Share by Type (2020-2025)
- Table 134. Global Remicade Biosimilar Revenue Market Share by Type (2026-2031)
- Table 135. Global Remicade Biosimilar Price by Type (2020-2025) & (US$/L)
- Table 136. Global Remicade Biosimilar Price by Type (2026-2031) & (US$/L)
- Table 137. Global Remicade Biosimilar Sales by Application (2020-2025) & (L)
- Table 138. Global Remicade Biosimilar Sales by Application (2026-2031) & (L)
- Table 139. Global Remicade Biosimilar Sales Market Share by Application (2020-2025)
- Table 140. Global Remicade Biosimilar Sales Market Share by Application (2026-2031)
- Table 141. Global Remicade Biosimilar Revenue by Application (2020-2025) & (US$ Million)
- Table 142. Global Remicade Biosimilar Revenue by Application (2026-2031) & (US$ Million)
- Table 143. Global Remicade Biosimilar Revenue Market Share by Application (2020-2025)
- Table 144. Global Remicade Biosimilar Revenue Market Share by Application (2026-2031)
- Table 145. Global Remicade Biosimilar Price by Application (2020-2025) & (US$/L)
- Table 146. Global Remicade Biosimilar Price by Application (2026-2031) & (US$/L)
- Table 147. Key Raw Materials
- Table 148. Raw Materials Key Suppliers
- Table 149. Remicade Biosimilar Distributors List
- Table 150. Remicade Biosimilar Customers List
- Table 151. Remicade Biosimilar Industry Trends
- Table 152. Remicade Biosimilar Industry Drivers
- Table 153. Remicade Biosimilar Industry Restraints
- Table 154. Authors List of This Report
- List of Figures
- Figure 1. Research Methodology
- Figure 2. Research Process
- Figure 3. Key Executives Interviewed
- Figure 4. Remicade Biosimilar Product Image
- Figure 5. Global Remicade Biosimilar Revenue (US$ Million), 2020 VS 2024 VS 2031
- Figure 6. Global Remicade Biosimilar Market Size (2020-2031) & (US$ Million)
- Figure 7. Global Remicade Biosimilar Sales (2020-2031) & (L)
- Figure 8. Global Remicade Biosimilar Average Price (US$/L) & (2020-2031)
- Figure 9. 100mg/10ml Product Image
- Figure 10. 500mg/50ml Product Image
- Figure 11. Blood Disorders Product Image
- Figure 12. Oncology Diseases Product Image
- Figure 13. Global Remicade Biosimilar Revenue Share by Manufacturers in 2024
- Figure 14. Global Manufacturers of Remicade Biosimilar, Manufacturing Sites & Headquarters
- Figure 15. Global Top 5 and 10 Remicade Biosimilar Players Market Share by Revenue in 2024
- Figure 16. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 17. Global Remicade Biosimilar Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Figure 18. Global Remicade Biosimilar Sales by Region in 2024
- Figure 19. Global Remicade Biosimilar Revenue by Region in 2024
- Figure 20. North America Remicade Biosimilar Market Size by Country in 2024
- Figure 21. North America Remicade Biosimilar Sales Market Share by Country (2020-2031)
- Figure 22. North America Remicade Biosimilar Revenue Market Share by Country (2020-2031)
- Figure 23. United States Remicade Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 24. Canada Remicade Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 25. Europe Remicade Biosimilar Market Size by Country in 2024
- Figure 26. Europe Remicade Biosimilar Sales Market Share by Country (2020-2031)
- Figure 27. Europe Remicade Biosimilar Revenue Market Share by Country (2020-2031)
- Figure 28. Germany Remicade Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 29. France Remicade Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 30. U.K. Remicade Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 31. Italy Remicade Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 32. Netherlands Remicade Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 33. Nordic Countries Remicade Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 34. Asia Pacific Remicade Biosimilar Market Size by Country in 2024
- Figure 35. Asia Pacific Remicade Biosimilar Sales Market Share by Country (2020-2031)
- Figure 36. Asia Pacific Remicade Biosimilar Revenue Market Share by Country (2020-2031)
- Figure 37. China Remicade Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 38. Japan Remicade Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 39. South Korea Remicade Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 40. India Remicade Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 41. Australia Remicade Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 42. China Taiwan Remicade Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 43. Southeast Asia Remicade Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 44. Southeast Asia Remicade Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 45. South America Remicade Biosimilar Market Size by Country in 2024
- Figure 46. South America Remicade Biosimilar Sales Market Share by Country (2020-2031)
- Figure 47. South America Remicade Biosimilar Revenue Market Share by Country (2020-2031)
- Figure 48. Mexico Remicade Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 49. Brazil Remicade Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 50. Argentina Remicade Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 51. Middle East and Africa Remicade Biosimilar Market Size by Country in 2024
- Figure 52. Middle East and Africa Remicade Biosimilar Sales Market Share by Country (2020-2031)
- Figure 53. Middle East and Africa Remicade Biosimilar Revenue Market Share by Country (2020-2031)
- Figure 54. Turkey Remicade Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 55. Saudi Arabia Remicade Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 56. UAE Remicade Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 57. Global Remicade Biosimilar Sales Market Share by Type (2020-2031)
- Figure 58. Global Remicade Biosimilar Revenue Market Share by Type (2020-2031)
- Figure 59. Global Remicade Biosimilar Price (US$/L) by Type (2020-2031)
- Figure 60. Global Remicade Biosimilar Sales Market Share by Application (2020-2031)
- Figure 61. Global Remicade Biosimilar Revenue Market Share by Application (2020-2031)
- Figure 62. Global Remicade Biosimilar Price (US$/L) by Application (2020-2031)
- Figure 63. Remicade Biosimilar Value Chain
- Figure 64. Remicade Biosimilar Production Mode & Process
- Figure 65. Direct Comparison with Distribution Share
- Figure 66. Distributors Profiles
- Figure 67. Remicade Biosimilar Industry Opportunities and Challenges
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
